PDF(Pubmed)
Abstract：
OBJECTIVE: The optimal timing for surgery following neoadjuvant immunochemotherapy for lung squamous cell carcinoma appears to be a topic of limited data. Many clinical studies lack stringent guidelines regarding this timing. The objective of this study is to explore the effect of the interval between neoadjuvant immunochemotherapy and surgery on survival outcomes in patients with lung squamous cell carcinoma.
METHODS: This study conducted a retrospective analysis of patients with lung squamous cell carcinoma who underwent neoadjuvant immunochemotherapy between January 2019 and October 2022 at The First Affiliated Hospital, Zhejiang University School of Medicine. Patients were divided into two groups based on the treatment interval: ≤33 days and > 33 days. The primary observational endpoints of the study were Disease-Free Survival (DFS) and Overall Survival (OS). Secondary observational endpoints included Objective response rate (ORR), Major Pathological Response (MPR), and Pathological Complete Remission (pCR).
RESULTS: Using the Kaplan-Meier methods, the ≤ 33d group demonstrated a superior DFS curve compared to the > 33d group (p = 0.0015). The median DFS for the two groups was 952 days and 590 days, respectively. There was no statistical difference in the OS curves between the groups (p = 0.66), and the median OS was not reached for either group. The treatment interval did not influence the pathologic response of the tumor or lymph nodes.
CONCLUSIONS: The study observed that shorter treatment intervals were associated with improved DFS, without influencing OS, pathologic response, or surgical safety. Patients should avoid having a prolonged treatment interval between neoadjuvant immunochemotherapy and surgery.
METHODS: This study conducted a retrospective analysis of patients with lung squamous cell carcinoma who underwent neoadjuvant immunochemotherapy between January 2019 and October 2022 at The First Affiliated Hospital, Zhejiang University School of Medicine. Patients were divided into two groups based on the treatment interval: ≤33 days and > 33 days. The primary observational endpoints of the study were Disease-Free Survival (DFS) and Overall Survival (OS). Secondary observational endpoints included Objective response rate (ORR), Major Pathological Response (MPR), and Pathological Complete Remission (pCR).
RESULTS: Using the Kaplan-Meier methods, the ≤ 33d group demonstrated a superior DFS curve compared to the > 33d group (p = 0.0015). The median DFS for the two groups was 952 days and 590 days, respectively. There was no statistical difference in the OS curves between the groups (p = 0.66), and the median OS was not reached for either group. The treatment interval did not influence the pathologic response of the tumor or lymph nodes.
CONCLUSIONS: The study observed that shorter treatment intervals were associated with improved DFS, without influencing OS, pathologic response, or surgical safety. Patients should avoid having a prolonged treatment interval between neoadjuvant immunochemotherapy and surgery.
摘要：
目的：肺鳞状细胞癌新辅助免疫化疗后手术的最佳时机似乎是一个有限数据的话题。许多临床研究缺乏关于这一时机的严格指南。本研究的目的是探讨新辅助免疫化疗与手术间隔时间对肺鳞癌患者生存结局的影响。
方法：本研究对2019年1月至2022年10月在第一附属医院接受新辅助免疫化疗的肺鳞癌患者进行回顾性分析。浙江大学医学院.根据治疗间隔将患者分为两组：≤33天和>33天。该研究的主要观察终点是无病生存率（DFS）和总生存率（OS）。次要观察终点包括客观缓解率（ORR），主要病理反应（MPR），病理完全缓解（pCR）。
结果：使用Kaplan-Meier方法，≤33d组的DFS曲线优于>33d组(p=0.0015).两组的中位DFS分别为952天和590天，分别。组间OS曲线无统计学差异(p=0.66),两组均未达到中位OS。治疗间隔不影响肿瘤或淋巴结的病理反应。
结论：该研究观察到较短的治疗间隔与改善的DFS相关，不影响操作系统，病理反应，或手术安全。患者应避免在新辅助免疫化疗和手术之间延长治疗间隔。
方法：本研究对2019年1月至2022年10月在第一附属医院接受新辅助免疫化疗的肺鳞癌患者进行回顾性分析。浙江大学医学院.根据治疗间隔将患者分为两组：≤33天和>33天。该研究的主要观察终点是无病生存率（DFS）和总生存率（OS）。次要观察终点包括客观缓解率（ORR），主要病理反应（MPR），病理完全缓解（pCR）。
结果：使用Kaplan-Meier方法，≤33d组的DFS曲线优于>33d组(p=0.0015).两组的中位DFS分别为952天和590天，分别。组间OS曲线无统计学差异(p=0.66),两组均未达到中位OS。治疗间隔不影响肿瘤或淋巴结的病理反应。
结论：该研究观察到较短的治疗间隔与改善的DFS相关，不影响操作系统，病理反应，或手术安全。患者应避免在新辅助免疫化疗和手术之间延长治疗间隔。
